LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
40 hedge funds and large institutions have $138M invested in LogicBio Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
8% more funds holding
Funds holding: 37 → 40 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less capital invested
Capital invested by funds: $165M → $138M (-$26.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$839K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$433K |
| 3 |
Goldman Sachs
New York
|
+$253K |
| 4 |
BlackRock
New York
|
+$165K |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$705K |
| 2 |
SCM
Sio Capital Management
New York
|
-$107K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$46.2K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$44K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$31.7K |
LOGC Hedge Fund Activity: Q3 2019 in Review
40 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q3 2019, worth a combined $138M — down 16% from $165M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LOGC positions and 1 closed out — a net gain of 3 holders — while 13 added to existing stakes and 11 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $839K. The largest seller was Redmile Group, cutting an estimated $705K.
- 40 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q3 2019, up from 37 in Q2 2019.
- Funds reported $138M of LogicBio Therapeutics, Inc. Common Stock stock for Q3 2019, down 16% quarter-over-quarter.
- 4 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q3 2019 and 1 closed out, a net change of +3 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q3 2019 was Adage Capital Partners, an estimated $839K added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q3 2019 was Redmile Group, an estimated $705K sold.
Based on aggregated 13F filings for Q3 2019.